JP Morgan Chase
TVRD

JP Morgan Chase’s Tvardi Therapeutics TVRD Stock Holding History

JP Morgan Chase’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.21K Buy
2,565
+86
+3% +$337 ﹤0.01% 6788
2025
Q4 		$10.7K Buy
2,479
+562
+29% +$5.04K ﹤0.01% 6655
2025
Q3 		$74.7K Buy
1,917
+249
+15% +$7.09K ﹤0.01% 6063
2025
Q2 		$38.9K Buy
1,668
+1,176
+239% +$27.8K ﹤0.01% 6006
2025
Q1 		$7.48K Buy
492
+31
+7% +$468 ﹤0.01% 6363
2024
Q4 		$8.46K Buy
461
+315
+216% +$3.43K ﹤0.01% 6419
2024
Q3 		$1.62K Sell
146
-1,933
-93% -$22.7K ﹤0.01% 6652
2024
Q2 		$19.3K Buy
2,079
+1,133
+120% +$27K ﹤0.01% 6148
2024
Q1 		$31K Buy
946
+81
+9% +$2.1K ﹤0.01% 6107
2023
Q4 		$23.1K Sell
865
-287
-25% -$11.9K ﹤0.01% 6220
2023
Q3 		$69.7K Buy
1,152
+11
+1% +$1.03K ﹤0.01% 5683
2023
Q2 		$116K Sell
1,141
-975
-46% -$134K ﹤0.01% 5399
2023
Q1 		$375K Buy
2,116
+202
+11% +$67.6K ﹤0.01% 4675
2022
Q4 		$739K Sell
1,914
-7,777
-80% -$2.95M ﹤0.01% 4255
2022
Q3 		$3.27M Sell
9,691
-271
-3% -$98.2K ﹤0.01% 3090
2022
Q2 		$3.27M Buy
9,962
+1,650
+20% +$579K ﹤0.01% 3149
2022
Q1 		$3.64M Sell
8,312
-982
-11% -$403K ﹤0.01% 3268
2021
Q4 		$4.08M Buy
9,294
+6,096
+191% +$3.06M ﹤0.01% 3241
2021
Q3 		$1.78M Buy
3,198
+805
+34% +$404K ﹤0.01% 3875
2021
Q2 		$1.23M Hold
2,393
– – ﹤0.01% 4155
2021
Q1 		$1.87M Sell
2,393
-344
-13% -$236K ﹤0.01% 3775
2020
Q4 		$1.49M Sell
2,737
-75
-3% -$39.3K ﹤0.01% 3700
2020
Q3 		$1.25M Sell
2,812
-158
-5% -$91.8K ﹤0.01% 3521
2020
Q2 		$1.83M Sell
2,970
-302
-9% -$167K ﹤0.01% 3163
2020
Q1 		$1.56M Sell
3,272
-459
-12% -$249K ﹤0.01% 3126
2019
Q4 		$2.16M Sell
3,731
-289
-7% -$203K ﹤0.01% 3330
2019
Q3 		$2.65M Buy
4,020
+194
+5% +$161K ﹤0.01% 3224
2019
Q2 		$2.91M Buy
3,826
+58
+2% +$40.8K ﹤0.01% 3111
2019
Q1 		$2.66M Sell
3,768
-10
-0.3% -$5.99K ﹤0.01% 3132
2018
Q4 		$1.77M Buy
3,778
+74
+2% +$47.7K ﹤0.01% 3365
2018
Q3 		$3.19M Sell
3,704
-4,939
-57% -$3.57M ﹤0.01% 3109
2018
Q2 		$5.96M Sell
8,643
-431
-5% -$219K ﹤0.01% 2540
2018
Q1 		$4.04M Sell
9,074
-783
-8% -$380K ﹤0.01% 2758
2017
Q4 		$4.34M Sell
9,857
-140
-1% -$63.8K ﹤0.01% 2793
2017
Q3 		$4.79M Sell
9,997
-174
-2% -$87.1K ﹤0.01% 2593
2017
Q2 		$5.63M Buy
10,171
+540
+6% +$343K ﹤0.01% 2398
2017
Q1 		$6.38M Sell
9,631
-570
-6% -$304K ﹤0.01% 2265
2016
Q4 		$3.41M Sell
10,201
-74
-0.7% -$23.7K ﹤0.01% 2731
2016
Q3 		$3.09M Sell
10,275
-1,527
-13% -$331K ﹤0.01% 2540
2016
Q2 		$2.04M Sell
11,802
-2,459
-17% -$535K ﹤0.01% 2794
2016
Q1 		$3.19M Buy
14,261
+4,550
+47% +$1.36M ﹤0.01% 2453
2015
Q4 		$5.89M Sell
9,711
-1,054
-10% -$579K ﹤0.01% 2119
2015
Q3 		$5.54M Buy
10,765
+5,275
+96% +$3.53M ﹤0.01% 2158
2015
Q2 		$2.4M Sell
5,490
-2,145
-28% -$829K ﹤0.01% 2805
2015
Q1 		$2.76M Sell
7,635
-1,155
-13% -$437K ﹤0.01% 2707
2014
Q4 		$3.15M Sell
8,790
-1,036
-11% -$334K ﹤0.01% 2703
2014
Q3 		$2.97M Sell
9,826
-24
-0.2% -$9.86K ﹤0.01% 2674
2014
Q2 		$6.04M Sell
9,850
-271
-3% -$146K ﹤0.01% 1986
2014
Q1 		$6.78M Buy
+10,121
New +$5.99M ﹤0.01% 1918

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

JP Morgan Chase's TVRD Position: Q1 2026 in Review

JP Morgan Chase increased its Tvardi Therapeutics (TVRD) stake by 3.5% in Q1 2026, buying an estimated $337 and bringing the position to 2,565 shares worth $8.21K. The position accounts for ﹤0.01% of the portfolio, ranked #6788.

JP Morgan Chase first reported a position in TVRD in Q1 2014 and has held it in 49 quarters since. The position peaked at $6.78M in Q1 2014. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • JP Morgan Chase held 2,565 shares of Tvardi Therapeutics worth $8.21K as of Q1 2026.
  • JP Morgan Chase bought 86 Tvardi Therapeutics shares in Q1 2026, an estimated $337.
  • Tvardi Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6788 holding.
  • JP Morgan Chase first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • JP Morgan Chase's Tvardi Therapeutics position peaked at $6.78M in Q1 2014.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.